Medical Complications of Immunosuppression

作者: Jerry McCauley , Ron Shapiro

DOI: 10.1007/978-94-010-0765-8_17

关键词:

摘要: Transplantation effectively owes its existence to the development of immunosuppressive agents. Loss allografts all types acute rejection has become less frequent as potency and variety agents continued improve. Unfortunately, medical complications transplantation are also largely related these Each one been associated with well-described side effects, which must be anticipated managed by physicians caring for patients. There is a growing recognition that patient graft survival may highly influenced effects Cardiovascular disease leading cause death in transplant patients, progression accelerated various Likewise, loss caused chronic allograft after first two years. The influence hyperlipidemia other factors play major role this process. Proper management offer an important opportunity prevent premature loss.

参考文章(40)
I Penn, THE CHANGING PATTERN OF POSTTRANSPLANT MALIGNANCIES International congress of the transplantation society. ,vol. 23, pp. 1101- 1103 ,(1991)
Y Vanrenterghem, H Ekberg, J Grinyo, G Tufveson, C Groth, D Cantarovich, L Mjornstedt, S Sadek, R Pichlmayr, F Moreso, G Gannedahl, P Lang, Adam Tegzess, J Rodicio, van Willem Son, A Morgan, A Tarantino, J Peeters, M Campise, J Lodge, K Hutchinson, J Erhard, K Wagner, L Hooftman, S Carl, G Ligtenberg, G Thiel, R Luck, M Wiesel, M Zeiler, Hh Neumayer, Sa Sadek, Jp Soulillou, K Rigg, B Bourgeon, P Fauchald, Hauser, C Brattstrom, R Hene, M Behrend, D Albrechtsen, N Persson, J Morales, PLACEBO-CONTROLLED STUDY OF MYCOPHENOLATE MOFETIL COMBINED WITH CYCLOSPORINE AND CORTICOSTEROIDS FOR PREVENTION OF ACUTE REJECTION The Lancet. ,vol. 345, pp. 1321- 1325 ,(1995)
Richard M. Weinshilboum, Susan L. Sladek, Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. American Journal of Human Genetics. ,vol. 32, pp. 651- 662 ,(1980)
Robert G Luke, None, Pathophysiology and treatment of posttransplant hypertension. Journal of The American Society of Nephrology. ,vol. 2, ,(1991) , 10.1681/ASN.V22S37
M R First, L L Rocher, A Tejani, J F Neylan, Hypertension after renal transplantation. Journal of The American Society of Nephrology. ,vol. 4, ,(1994) , 10.1681/ASN.V48S30
D. A. Laskow, J. J. Curtis, Post-Transplant Hypertension American Journal of Hypertension. ,vol. 3, pp. 721- 725 ,(1990) , 10.1093/AJH/3.9.721
RAHUL M JINDAL, IRINEL POPESCU, MYRON E SCHWARTZ, SUKRU EMRE, PATRIZIA BOCCAGNI, CHARLES M MILLER, Diabetogenicity of FK506 versus cyclosporine in liver transplant recipients. Transplantation. ,vol. 58, pp. 370- 371 ,(1994) , 10.1097/00007890-199408000-00021
Maria G. Murgia, Samantha Jordan, Barry D. Kahan, The side effect profile of sirolimus: A phase I study in quiescent cyclosporine-prednisone-treated renal transplant patients Kidney International. ,vol. 49, pp. 209- 216 ,(1996) , 10.1038/KI.1996.28
Robert Mendez, Roger Satterthwaite, Saleh Aswad, Victor Sunga, Hamid Shidban, Thomas Bogaard, Paul Asai, Umakant Khetan, Iklas Akra, Rafael G. Mendez, Incidence of new-onset hypercholesterolemia in renal transplant patients treated with FK506 or cyclosporine. Transplantation. ,vol. 65, pp. 446- 449 ,(1998) , 10.1097/00007890-199802150-00030
Donald E. Hricik, Posttransplant Hyperlipidemia: The Treatment Dilemma American Journal of Kidney Diseases. ,vol. 23, pp. 766- 771 ,(1994) , 10.1016/S0272-6386(12)70291-3